Add an Antidepressant to the Current Regimen
For a patient on aripiprazole 12 mg with buspirone who continues to experience depressed mood, add a selective serotonin reuptake inhibitor (SSRI) such as escitalopram, sertraline, or fluoxetine, or consider switching to a serotonin-norepinephrine reuptake inhibitor (SNRI) like venlafaxine or duloxetine.
Clinical Reasoning
Aripiprazole at 12 mg is being used for depression, but this is an atypical antipsychotic that lacks FDA approval as monotherapy for major depressive disorder. The FDA label for aripiprazole indicates it is approved only as adjunctive treatment to antidepressants for major depressive disorder 1. The patient appears to be receiving aripiprazole without a primary antidepressant, which represents suboptimal treatment.
Buspirone is an anxiolytic that may provide modest antidepressant augmentation effects, but it is not a first-line treatment for depression 2, 3. The persistent depressed mood indicates inadequate treatment of the underlying depressive disorder.
Treatment Algorithm
Step 1: Add a Primary Antidepressant
Start an SSRI or SNRI as the foundation of depression treatment:
- SSRIs: Escitalopram 10-20 mg daily, sertraline 50-200 mg daily, or fluoxetine 20-60 mg daily
- SNRIs: Venlafaxine extended-release 75-225 mg daily or duloxetine 40-60 mg daily
SNRIs may have a slight efficacy advantage over SSRIs for depression symptoms, though they carry higher rates of nausea and vomiting 4. For treatment-naive patients, all second-generation antidepressants show equal effectiveness, so selection should be based on side effect profiles, cost, and dosing convenience 4.
Step 2: Continue Aripiprazole as Adjunctive Treatment
Maintain aripiprazole 12 mg as adjunctive therapy once the antidepressant is started. This aligns with its FDA-approved indication 1. Research supports aripiprazole's effectiveness when combined with antidepressants for treatment-resistant depression 5, 6. The combination of aripiprazole with mood stabilizers or antidepressants shows efficacy for depressive symptoms 7, 8.
Step 3: Maintain or Adjust Buspirone
Continue buspirone for anxiety management. Evidence suggests buspirone augmentation of SSRIs can improve both anxiety and depressive symptoms 2, 3. If anxiety is well-controlled, buspirone can be maintained at current dose. If anxiety persists, consider increasing buspirone to 30-60 mg daily in divided doses.
Important Drug Interactions
Critical consideration: If selecting fluoxetine or paroxetine as the antidepressant, reduce aripiprazole dose to 6 mg daily (half the usual dose) because these are strong CYP2D6 inhibitors that significantly increase aripiprazole exposure 1. Other SSRIs like escitalopram and sertraline do not require aripiprazole dose adjustment 1.
Monitoring Plan
- Assess response at 2-4 weeks initially, then every 4-6 weeks 4
- Monitor for activation, agitation, or worsening suicidality, particularly in the first 4-8 weeks 1
- Watch for metabolic side effects from aripiprazole (weight gain, glucose changes), though aripiprazole has lower metabolic burden than other atypical antipsychotics 5
- Continue treatment for at least 4-9 months after achieving remission for a first depressive episode 4
Common Pitfalls to Avoid
Do not use aripiprazole as monotherapy for depression—it requires combination with an antidepressant for FDA-approved use in major depressive disorder 1. The current regimen lacks a primary antidepressant agent, which is the likely reason for persistent depressed mood.
Do not assume buspirone alone provides adequate antidepressant effects—while it may augment antidepressant therapy, it is primarily an anxiolytic 2, 3.
Do not forget dose adjustments when combining aripiprazole with strong CYP2D6 or CYP3A4 inhibitors 1.